VIR
NASDAQVir Biotechnology Inc.
News · 26 weeks46+67%
2026-03-012026-08-23
Mix2290d
- Insider11(50%)
- SEC Filings6(27%)
- Earnings2(9%)
- Leadership1(5%)
- Offering1(5%)
- Other1(5%)
Latest news
25 items- INSIDERDirector More Robert J disposed of 8,000 shares and acquired 8,000 shares, decreasing direct ownership by 16% to 40,656 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Vir Biotechnology Inc.SCHEDULE 13G - Vir Biotechnology, Inc. (0001706431) (Subject)
- SECSEC Form 10-Q filed by Vir Biotechnology Inc.10-Q - Vir Biotechnology, Inc. (0001706431) (Filer)
- SECVir Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Provides Corporate Update and Reports Second Quarter 2026 Financial Results- Phase 2 SOLSTICE data presented at the EASL Congress showed that elebsiran and tobevibart achieved undetectable HDV RNA in 88% of participants with chronic hepatitis delta (CHD) at Week 96 of treatment - Topline data from Phase 3 ECLIPSE 1 trial expected in the fourth quarter of 2026 - Closed global strategic collaboration with Astellas and initiated additional VIR-5500 Phase 1 monotherapy and combination therapy dose-expansion cohorts in patients with metastatic prostate cancer - Ended quarter with over $1.0 billion in cash, cash equivalents and investments - Conference call scheduled for August 5, 2026, at 4:30 p.m. ET / 1:30 p.m. PT Vir Biotechnology, Inc. (NASDAQ:VIR), today
- SECVir Biotechnology Inc. filed SEC Form 8-K: Leadership Update8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Announces Chief Financial Officer TransitionVir Biotechnology, Inc. (NASDAQ:VIR) today announced that Brent Sabatini, Senior Vice President and Chief Accounting Officer, has been appointed Interim Principal Financial Officer, effective July 23. Jason O’Byrne is leaving the Company to pursue another opportunity and will remain with Vir Biotechnology through August 3 to ensure a smooth transition. The Company has initiated a comprehensive search to identify its next Chief Financial Officer."Brent has deep institutional knowledge and financial acumen and has played a significant role in our strategic business development efforts and latest public offering, which helped to establish a strong cash position for the Company," said Marianne D
- PRVir Biotechnology to Host Conference Call for Second Quarter 2026 Financial ResultsVir Biotechnology, Inc. (NASDAQ:VIR) today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, August 5 to provide a corporate update and discuss its financial results for the second quarter ended June 30, 2026. The conference call may be accessed on the Events & Presentations page of the Vir Biotechnology website.About Vir BiotechnologyVir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T
- SECSEC Form 144 filed by Vir Biotechnology Inc.144 - Vir Biotechnology, Inc. (0001706431) (Subject)
- INSIDERDirector Coughlin Timothy was granted 16,000 units of Common Stock (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERNew insider Coughlin Timothy claimed no ownership of stock in the company (SEC Form 3)3 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- SECVir Biotechnology Inc. filed SEC Form 8-K: Leadership Update8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology Announces Appointment of Timothy Coughlin to its Board of DirectorsVir Biotechnology, Inc. (NASDAQ:VIR) today announced the appointment of Timothy Coughlin to its Board of Directors and as Chair of the Audit Committee, effective June 9, 2026. "We are pleased to welcome Tim to Vir Biotechnology's Board of Directors at a pivotal moment for the company," said Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. "Tim brings a strong background of strategic discipline and operational insight that has helped organizations evolve into fully integrated enterprises. His extensive experience as chief financial officer and board member spanning discovery through commercialization will be highly valuable as we advance our portfolio. We
- INSIDERDirector Napolitano Janet sold $30,240 worth of shares (3,200 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 21,216 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERSVP, Chief Accounting Officer Sabatini Brent sold $3,582 worth of Common Stock (379 units at $9.45) as part of a pre-agreed trading plan, decreasing direct ownership by 0.61% to 61,902 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector Sigal Charles Elliott was granted 8,000 shares, increasing direct ownership by 25% to 39,806 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector Napolitano Janet was granted 8,000 shares, increasing direct ownership by 49% to 24,416 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector More Robert J was granted 8,000 shares, increasing direct ownership by 20% to 48,656 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector Hatfield Jeffrey S. was granted 8,000 shares, increasing direct ownership by 25% to 39,806 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector Farid Ramy was granted 8,000 shares, increasing direct ownership by 33% to 32,000 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- INSIDERDirector Bischofberger Norbert W was granted 8,000 shares, increasing direct ownership by 60% to 21,333 units (SEC Form 4)4 - Vir Biotechnology, Inc. (0001706431) (Issuer)
- SECVir Biotechnology Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
- PRVir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026- Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48 subgroup analysis from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for poster tour by EASL Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta at the upcoming EASL Congress 2026 in Barcelona, Spain, May 27-30, 2026. Efficacy and safety of tobevibart (VIR-3434) alone or in combination with elebsiran (VIR-2218) in participants with chro
- PR"Cold" Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesIssued on behalf of GT Biopharma, Inc. After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, and other historically immunotherapy-resistant solid tumors are suddenly among the busiest battlegrounds in oncology — and a new natural killer cell engager just joined the field SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- World Street Intelligence News Commentary — Until very recently, the immuno-oncology revolution had largely passed several of the most lethal solid tumor categories by. Checkpoint inhibitors, which transformed outcomes in melanoma, lung cancer, and renal cell carcinoma, have struggled to deliver meaningful benefit for the m
- SECVir Biotechnology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Vir Biotechnology, Inc. (0001706431) (Filer)
VIR FAQ
7 questionsWhat does Vir Biotechnology Inc. do?
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus; and VIR-2020 for the prevention of tuberculosis. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration...Where does VIR stock trade?
Vir Biotechnology Inc. (VIR) is listed on NASDAQ.What sector and industry is VIR in?
Vir Biotechnology Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Vir Biotechnology Inc. go public?
Vir Biotechnology Inc. (VIR) completed its IPO in 2019.What are analysts saying about VIR?
Vir Biotechnology Inc. has had 8 recent analyst actions on file. The most recent action was from Raymond James: Strong Buy with a $1900.00 price target on 2026-02-24. Recent price targets range from $900.00 to $3400.00.What companies are similar to VIR?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), MRNA (Moderna Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.). Compare VIR side-by-side with any of them on Quantisnow.How can I track VIR on Quantisnow?
Quantisnow aggregates Vir Biotechnology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VIR to receive live email and push alerts on every new disclosure.